Dyne Therapeutics’ (DYN) Outperform Rating Reaffirmed at Royal Bank of Canada

Dyne Therapeutics (NASDAQ:DYN)‘s stock had its “outperform” rating reiterated by Royal Bank of Canada in a research note issued on Tuesday,Benzinga reports. They presently have a $45.00 price target on the stock. Royal Bank of Canada’s price target points to a potential upside of 198.21% from the company’s current price.

Several other research analysts have also issued reports on DYN. Piper Sandler restated an “overweight” rating and issued a $53.00 price target on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Robert W. Baird started coverage on Dyne Therapeutics in a report on Friday, December 13th. They set an “outperform” rating and a $46.00 target price on the stock. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. JPMorgan Chase & Co. cut shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $43.00 to $35.00 in a report on Thursday, October 24th. Finally, Chardan Capital reiterated a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Friday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Dyne Therapeutics has an average rating of “Moderate Buy” and an average price target of $49.91.

Dyne Therapeutics Stock Down 1.3 %

DYN stock traded down $0.20 during midday trading on Tuesday, reaching $15.09. The stock had a trading volume of 335,713 shares, compared to its average volume of 2,268,373. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -4.24 and a beta of 1.16. Dyne Therapeutics has a twelve month low of $14.79 and a twelve month high of $47.45. The business has a fifty day simple moving average of $26.77 and a two-hundred day simple moving average of $33.88.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, equities analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In related news, SVP Richard William Scalzo sold 1,455 shares of the firm’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the transaction, the senior vice president now owns 127,078 shares of the company’s stock, valued at approximately $3,573,433.36. This trade represents a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Carlo Incerti sold 16,500 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $28.73, for a total transaction of $474,045.00. The disclosure for this sale can be found here. Insiders have sold 44,742 shares of company stock valued at $1,443,246 in the last 90 days. 20.77% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Quantbot Technologies LP bought a new stake in shares of Dyne Therapeutics in the 3rd quarter valued at about $34,000. Point72 DIFC Ltd acquired a new position in Dyne Therapeutics during the third quarter worth approximately $36,000. US Bancorp DE increased its position in Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after buying an additional 1,212 shares during the last quarter. Values First Advisors Inc. bought a new stake in Dyne Therapeutics in the third quarter valued at approximately $62,000. Finally, KBC Group NV lifted its position in shares of Dyne Therapeutics by 53.4% in the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after buying an additional 751 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.